Impact of the National Service Framework for coronary heart disease on treatment and outcome of patients with acute coronary syndromes

Heart

Volumn 92, Issue 3, 2006, Pages 301-306

  Graham, J J ^a   Timmis, A ^a,c   Cooper, J ^b   Ramdany, S ^a   Deaner, A ^a   Ranjadayalan, K ^c   Knight, Charles ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NEWHAM UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CORONARY CARE UNIT; EMERGENCY TREATMENT; FEMALE; FIBRINOLYTIC THERAPY; GENERAL HOSPITAL; HEART CATHETERIZATION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCRIPTION; PRIORITY JOURNAL; Q WAVE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; COHORT STUDIES; CORONARY CARE UNITS; CORONARY DISEASE; EMERGENCY TREATMENT; FEMALE; HEART CATHETERIZATION; HOSPITAL MORTALITY; HOSPITALS, DISTRICT; HOSPITALS, GENERAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LONDON; MALE; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; SYNDROME; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644536423     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.051466     Document Type: Article

References (12)

1. Department of Health. White Paper on Public Health. Saving lives: our healthier nation. London: The Stationery Office, 1999.
2. Department of Health. National service framework for coronary heart disease: modern standards and service models. London: Department of Health, 2000.
3. Rhodes M, Newman C, Read S. National service framework for coronary heart disease: audit of English hospitals. BMJ 2002;324:709.
4. Stevenson R, Ranjadayalan K, Wilkinson P, et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolytic therapy. BMJ 1993;307:349-53.
5. Wilkinson P, Sayer J, Laji K, et al. Comparison of case fatality in South Asian and white patients following acute myocardial infarction. BMJ 1996;312:1330-3.
6. The HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000;342:145-53.
7. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC-II prospective randomised multicentre study. Lancet 1999;354:708-15.
8. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 1988;ii, 349-60.
9. Petch M. Heart disease, guidelines, regulations, and the law. Heart 2002;87:472-9.
10. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the cooperative cardiovascular project. JAMA 1998;279:1352-7.
11. Iliadis EA, Klein LW, Vandenberg BJ, et al. Clinical practice guidelines in unstable angina improve clinical outcomes by assuring early intensive medical treatment. J Am Coll Cardiol 1999;34:1689-95.
12. Goodman NW. Clinical governance: vision or mirage? J Eval Clin Pract 2002;8:243-9.